Mylan Inc. today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its ANDA for Felodipine Extended-release Tablets USP, 2.5 mg, 5 mg and 10 mg.
Felodipine Extended-release Tablets USP are the generic version of AstraZeneca Pharmaceutical's Plendil(R) Extended-release tablets, which had U.S. sales of approximately $251 million for the 12 months ending Dec. 31, 2007, according to IMS Health.
No comments:
Post a Comment